Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
Sponsor: Peking Union Medical College Hospital
This PHASE2 trial investigates Effects of Chemotherapy and Non-small Cell Lung Cancer and is currently ongoing. Peking Union Medical College Hospital leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking Union Medical College Hospital
For direct contact, visit the study record on ClinicalTrials.gov .